牧原股份近日登陆港交所，成为国内生猪养殖行业首家实现"A+H"双上市的企业。作为全球出栏量最大 的养猪企业，牧原股份借此为其国际化战略搭建了投融资渠道，但也带来新的经营课题。 不过双线并行也有许多风险需要注意。中国企业资本联盟副理事长柏文喜提示，"A+H"布局需重点警惕 估值落差、监管差异、治理整合三类风险。港股机构投资者占比高，对生猪养殖等强周期、重资产、利 润波动大的行业估值显著低于A股，可能会导致H股股价表现低于预期，影响融资效率。两地在会计准 则、信息披露等监管规则上也存在差异，企业需调整财务与治理体系以适配港股要求，防范因合规问题 导致的股价波动或罚款。此外，国际投资者更看重公司治理与长期战略，牧原作为A股企业，过去更注 重规模扩张，整合过程中可能出现理念冲突，影响决策效率。 多家投资机构入局 牧原股份H股发行引入了多家机构作为基石投资者，正大集团、丰益、中化香港、香港豫农国际、富达 基金、高毅、平安人寿保险、UBS AM等机构均在列，涵盖国际产业龙头、全球顶级资产管理机构等多 元主体。基石投资者合计认购金额约53.42亿港元，占全球发售股份的50%。 下一步，牧原股份不仅需要适配两地资本市场在监管 ...

Core Viewpoint - Marubi Biological has officially initiated its secondary listing process in Hong Kong, aiming to become one of the few domestic beauty giants with an "A+H" market presence, despite facing increased competition in the eye care product segment [1] Company Overview - Established in 2002, Marubi focuses on eye care research and gained prominence in 2007 with its popular eye cream, which helped it become the "first eye cream stock" upon its A-share listing in 2019 [1] - Marubi has maintained its position as the top seller in the eye care market in China for three consecutive years from 2021 to 2023 [1] Financial Performance - In 2024, Marubi reported a revenue of 2.97 billion yuan, representing a year-on-year growth of 33.44% - The net profit attributable to the parent company increased by 31.69% to 342 million yuan [1] Marketing and Brand Structure - The company has relied heavily on marketing for growth, with significant expenditures on advertising and traffic, while its research and development investment is relatively low compared to the industry [1] - The main brands "Marubi" and "Lianhuo" are experiencing growth, but the brand "Chunji" has seen a contraction [1] Competitive Landscape - Competitors such as Proya and Winona have launched similar eye care products, which has led to a squeeze on Marubi's market share [1] Regulatory Issues - In late October, Marubi was ordered to rectify issues related to financial accounting, fundraising management, and disclosure, leading to increased uncertainty regarding its IPO in Hong Kong [1]

Core Viewpoint - The ongoing trend of A-share companies listing in Hong Kong continues, with Junsheng Electronics being the latest to initiate its IPO, aiming to join the "A+H" market strategy [2][4]. Group 1: Company Overview - Junsheng Electronics plans to globally issue approximately 155 million H-shares, with 15.51 million shares available for public offering in Hong Kong and around 140 million shares for international placement [2]. - The company specializes in intelligent automotive technology solutions, focusing on the research, manufacturing, and sales of automotive components, particularly in automotive electronics and safety [4]. - Junsheng Electronics ranks 41st in the global automotive parts industry and is the second-largest supplier of passive safety products in China and globally, based on revenue [4]. Group 2: Financial Details - The expected maximum offer price for Junsheng Electronics is HKD 23.60 per share, with anticipated net proceeds from the global offering of approximately HKD 3.4585 billion [3]. - The allocation of net proceeds includes approximately 35% for R&D and commercialization of automotive intelligent solutions, 35% for improving manufacturing capabilities and supply chain management, 10% for expanding overseas market share, 10% for potential investments and acquisitions, and the remaining 10% for working capital and general corporate purposes [3]. Group 3: Timeline and Market Impact - The subscription period for Junsheng Electronics runs from October 28 to November 3, with H-shares expected to begin trading on the Hong Kong Stock Exchange on November 6 [4]. - The company has established cornerstone investment agreements with several investors, committing to a total of approximately USD 107.1 million for the shares being offered [2].

Core Viewpoint - Puyuan Precision Electric Technology Co., Ltd. (Puyuan Precision) is seeking to list on the Hong Kong Stock Exchange, aiming to enhance its competitiveness and brand image while utilizing international capital markets for diversified financing [2][11]. Company Overview - Puyuan Precision, established in 2000 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board since April 2022, has a market capitalization exceeding 7.9 billion RMB [3]. - The company is a leading provider of electronic measurement instruments in China, offering a comprehensive range of products and solutions, including digital oscilloscopes and RF instruments, primarily serving high-growth sectors such as communications, new energy, and semiconductors [3][6]. Market Position - According to Frost & Sullivan, Puyuan Precision is the largest electronic measurement instrument supplier in China and ranks eighth globally, with a market share of 1.1% [5][10]. - The company is recognized for its innovative products, being the first in China to commercialize digital oscilloscopes equipped with self-developed ASICs [5]. Financial Performance - Puyuan Precision's revenue from 2022 to 2025 is projected to grow from 631 million RMB to 776 million RMB, with stable profit margins and an EBITDA showing resilience [7][8]. - The company has maintained a gross profit margin of around 50% to 55% during this period, indicating strong operational efficiency [7]. Product and Revenue Breakdown - The revenue contribution from digital oscilloscopes has been significant, accounting for approximately 52.7% in 2022, gradually decreasing to 44.5% by 2025 [8]. - International sales represent a substantial portion of total revenue, with overseas sales accounting for 42.4% in 2022, although this is expected to decline slightly to 35.3% by 2024 [9]. Strategic Initiatives - The funds raised from the Hong Kong IPO will be allocated towards enhancing R&D capabilities, expanding production capacity, strategic investments, and strengthening global sales and marketing networks [13]. - The company has a significant cash reserve, with financial assets valued at 1.773 billion RMB as of July 2025, indicating a strong liquidity position [11].

Group 1 - Since August, nearly 20 A-share companies have announced plans to list in Hong Kong, with notable firms like Luxshare Precision and Victory Technology submitting H-share applications [1][5] - The primary motivations for these companies to pursue Hong Kong listings include expanding international strategies, optimizing overseas business layouts, enhancing brand recognition, and improving overseas financing capabilities [1][5] Group 2 - The recent A-share companies planning to list in Hong Kong span various industries, including electronics, machinery, pharmaceuticals, food and beverage, chemicals, and media, with the electronics sector being the most concentrated [5][6] - Companies like Kexing Pharmaceutical, a global biopharmaceutical firm, aim to deepen their "innovation + internationalization" strategy through the Hong Kong listing, which will accelerate overseas business development and enhance their international brand image [5][6] Group 3 - Electronic industry firms such as Jinghe Integration and Huqin Technology view the Hong Kong listing as a means to expand overseas customer bases and optimize investment layouts, which is crucial given the fast-paced product iteration and high technology investment in the sector [6] - Leading companies in their respective fields, such as Luxshare Precision and Victory Technology, have submitted H-share applications, with Luxshare Precision's market value exceeding 300 billion yuan and plans to use raised funds for capacity expansion and technological research [6] Group 4 - The new regulations effective from August 4 at the Hong Kong Stock Exchange have improved IPO market pricing and public market rules, enhancing financing flexibility for issuers and strengthening investor protection, which is expected to further encourage A-share companies to list in Hong Kong [6]

Core Viewpoint - The company plans to complete its H-share issuance and listing as part of its "innovation + internationalization" strategy, marking its first external equity financing since its A-share listing in 2000 [2][3]. Group 1: Timing and Market Context - The timeline for the company's Hong Kong listing has been rapid, with key milestones achieved within five months, reflecting a strategic response to the evolving pharmaceutical regulatory and market landscape in China [3]. - The international capital market's increasing acceptance of Chinese innovative drugs is a significant factor in the company's decision to list in Hong Kong, which serves as a bridge to global markets [5]. - The listing will provide the company with flexible financing tools to support its international expansion efforts [5]. Group 2: Strategic Goals and Achievements - The listing is aimed at expanding the company's overseas business and enhancing international research collaborations, thereby achieving breakthroughs in foreign markets [6]. - The current trend of high-quality Chinese companies listing in Hong Kong is expected to attract capital returning from a weakening US dollar [7]. - The company has made significant strides in its global presence, with products registered in over 40 countries and regions, and has established 14 global R&D centers [8]. Group 3: Financial Performance and Future Plans - The company reported a revenue of 27.985 billion yuan in 2024, a year-on-year increase of 22.6%, and a net profit of 6.337 billion yuan, up 47.3% [11]. - The funds raised from the listing will primarily be used for innovative drug development, international expansion, and operational capital, aiming to enhance its market presence [11]. - The company is positioned to transition from a domestic leader in innovative drugs to a global pharmaceutical player, with the Hong Kong listing seen as a starting point rather than an endpoint [11].